Abstract
Recently developed agents specifically acting on different 5-hydroxytryptamine (5-HT) receptor populations were used to analyze the functional role of 5-HT2 receptor subtypes in the sleep-wakefulness cycle of the rat. The 5-HT2 receptor antagonist ritanserin injected intraperitoneally (IP) (0.04–2.5 mg/kg) induced an increase in deep slow wave sleep (SWS2) duration at the expense of wakefulness (W), light slow wave sleep (SWS1) and paradoxical sleep (PS). The stimulation of 5-HT2 receptors by 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) produced a dose-related increase in W and a dose-dependent decrease in both SWS2 and PS. Pretreatment with ritanserin (0.16–2.5 mg/kg) or with cinanserin (2.5–5 mg/kg), another 5-HT2 receptor antagonist, dose-dependently reversed the W enhancement and the SWS2 deficit produced by DOM, but not the PS deficit. Sleep-wakefulness alterations (increase in W and SWS1 combined with a suppression of SWS2 and PS) observed after IP injection of two putative 5-HT1 receptor agonists, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) (2.5 mg/kg) and 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (RU 24969) (0.63 mg/kg), were not modified by ritanserin pretreatment (0.16–2.5 mg/kg). These results further support the hypothesis that the serotonergic system plays an active role in the regulation of the sleep-wakefulness cycle in the rat and that 5-HT2 receptors are involved in this action. In addition it is suggested that 5-HT1 receptor subtypes are unlikely to interact with 5-HT2 receptors in the sleep-wakefulness modulation mediated through 5-HT2 receptors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adrien J, Laguzzi R, Bourgoin S, Hamon M (1980) Le sommeil du rat à lésion précoce du raphé: pharmacologie du système sérotoninergique. Waking Sleeping 4:119–129.
Awouters F, Niemegeers CJE, Megens AHP, Meert TF, Janssen PAJ (1988) The pharmacological profile of ritanserin, a very specific central serotonin-5-HT2 antagonist. Drug Dev Res (in press)
Bourgoin S, Artaud F, Bockaert J, Hery F, Glowinski J, Hamon M (1978) Paradoxical decrease of brain 5-HT turnover by metergoline, a central 5-HT receptor blocker. Naunyn Schmiedebergs Arch Pharmacol 302:313–321.
Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richarson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576.
Cespuglio R, Riou F, Faradji H, Ponchon JL, Buda M, Gonon F, Jouvet M, Pujol JF (1979) The release of monoamines during the sleep waking cycle as studied with the voltametric technique. Neurosci Lett [Suppl] 3:S322.
Clarenbach P, Birmanns B, Krätzschmar S, Jaursch-Hancke C (1986) Sleep pattern and noctural plasma profiles of HGH, prolactin and cortisol in man after the serotonin-antagonist ritanserin and the GABA-agonist gabapentin. Sleep Res 15:29.
Colino A, Halliwell JV (1986) 8-OH-DPAT is a strong antagonist of 5-HT action in rat hippocampus. Eur J Pharmacol 130:151–152.
Colpaert FC, Meert TF, Niemegeers CJE, Janssen PAJ (1985) Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat. Psychopharmacology 86:45–54.
Conn PJ, Sanders-Bush E (1987) Central serotonin receptors: effector systems, physiological roles and regulation. Psychopharmacology 92:267–277.
Davenne D, Dugovic C, Franc B, Adrien J (1988) Ontogeny of slow wave sleep. In: Slow wave sleep: physiological, pathophysiological and functional aspects. Raven Press, New York (in press)
Declerck AC, Wauquier A, Van der Ham-Veltman PHM, Gelders Y (1987) Increase in slow-wave sleep in humans with the serotonin-5-HT2 antagonist ritanserin (the first exploratory polygraphic sleep study). Curr Ther Res Clin Exp 41:427–432.
Depoortere H, Riou-Merle F (1988) Differential effects of serotonergic agents on the sleep-wakefulness cycle in rats. In: Sleep 1986. Karger, Basel (in press)
Dugovic C, Wauquier A (1987) 5-HT2 receptors could be primarily involved in the regulation of slow wave sleep in the rat. Eur J Pharmacol 137:145–146.
Dzoljic MR, Saxena PR, Ukponmwan OE (1987) 5-HT2 receptor agonists enhance alertness. Sleep Res 16:88.
Enjalbert A, Hamon M, Bourgoin S, Adrien J, Bockaert J (1978) Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system. I. Development and distribution of serotonin and dopamine sensitive adenylate cyclase in rat and guinea pig brain. Mol Pharmacol 14:1–10.
Florio V, Lipparini F, Scotti de Carolis A, Longo VG (1969) EEG and behavioral effects of 2-5-methoxy-4-methyl-amphetamine (DOM, STP). Arch Int Pharmacodyn Ther 180:81–88.
Fornal C, Radulovacki M (1981) Sleep suppressant action of quipazine: relation to central serotonergic stimulation. Pharmacol Biochem Behav 15:937–944.
Fuxe K, Kiianmaa K (1978) 5-Hydroxytryptamine neurons and the sleep wakefulness cycle. Effects of methergoline and zimeldine. Neurosci Lett 8:55–58.
Gaillard JM (1983) Biochemical pharmacology of paradoxical sleep.Br J Clin Pharmacol 16:205S-230S
Gozlan H, El Mestikawy S, Pichat L, Glowinski J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand 3H-PAT. Nature 305:140–142.
Gradin K, Pettersson A, Hedner T, Persson B (1985) Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat. J Neural Transm 64:145–149.
Green AR, Guy AP, Gardner CR (1984) The behavioural effects of RU 24969, a suggested 5-HT1 receptor agonist in rodents and the effect on the behaviour of treatment with antidepressants. Neuropharmacology 23:655–661.
Hamon M, Mallat M, Herbet A, Nelson DL, Audinot M, Pichat L, Glowinski J (1981) [3H]Metergoline: a new ligand of serotonin receptors in the rat brain. J Neurochem 36:613–626.
Hedner T, Pettersson A, Persson B (1987) Chronic 5-HT2-receptor blockade by ritanserin does not reduce blood pressure in patients with essential hypertension. Acta Med Scand 222:307–310.
Idzikowski C, Cowen PJ, Nutt D, Mills FJ (1987) The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to l-tryptophan. Psychopharmacology 93:416–420.
Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytryptamine-2-antagonist increases human slow wave sleep. Brain Res 378:164–168.
Jouvet M (1969) Biogenic amines and the states of sleep. Science 163:32–41.
Jouvet M (1983) Hypnogenic indolamine-dependent factors and paradoxical sleep rebound. In: Sleep 1982. Karger, Basel, pp 2–18.
Kehr W (1977) Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain. Eur J Pharmacol 41:261–273.
Laguzzi R (1981) Effects of intraventricular injection of methiotepin and metergoline on the sleep stage in the rat. CR Soc Biol (Paris) 175:160–163.
Leysen JE (1988) Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton, Baker and Juorio (eds) Neuromethods, vol 12. Drugs as tools in neurotransmitter research. The Humana Press Inc., Clifton (in press)
Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978) Serotonergic component of neuroleptic receptors. Nature 272:168–171.
Leysen JE, Awouters F, Kennis L, Laduron PM, Vandenberck J, Janssen PAJ (1981) Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci 28:1015–1022.
Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen P, Laduron PM (1985) Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long-acting serotonin-5-HT2 antagonist. Mol Pharmacol 27:600–611.
McGinty DJ, Harper RM (1976) Dorsal raphe neurons: depression of firing during sleep in cats. Brain Res 101:569–575.
Mendelson WB, Jacobs LS, Reichman JD, Othmer E, Cryer PE, Trivedi B, Daughaday WH (1975) Methysergide: suppression of sleep related prolactin excretion and enhancement of sleep related growth hormone secretion. J Clin Invest 56:690–697.
Michel F, Klein M, Jouvet D, Valatx JL (1961) Etude polygraphique du sommeil chez le rat. CR Soc Biol (Paris) 155:2389–2392.
Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino) tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90:151–153.
Oswald I, Adam K, Spiegel R (1982) Human EEG slow-wave sleep increased by a serotonin antagonist. Electroencephalogr Clin Neurophysiol 54:583–586.
Paiva T, Arriaga F, Wauquier A, Lara E, Largo R, Leitao JN (1988) Changes in sleep disturbances of dysthymic patients induced by ritanserin. In: Slow wave sleep: physiological, pathophysiological and functional aspects. Raven Press, New York (in press)
Pedigo NW, Yamamura HI, Nelson DL (1981) Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36:220–226.
Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of 3H-5-hydroxytryptamine, 3H-lysergic acid diethylamide and 3H-spiroperidol. Mol Pharmacol 16:687–699.
Puizillout JJ, Gaudin-Chazal G, Daszuta A, Seyfritz N, Ternaux JN (1979) Release of endogenous serotonin from “encéphale isolé” cats. II. Correlations with raphe neuronal activity and sleep and wakefulness. J Physiol (Paris) 75:531–537.
Radulovacki M (1982) l-Tryptophan's effects on brain chemistry and sleep in cats and rats: a review. Neurosci Biobehav Rev 6:421–427.
Sallanon M, Buda C, Janin M, Jouvet M (1982) 5-HT antagonists suppress sleep and delay its restoration after 5-HTP in p-chlorophenylalanine-pretreated cats. Eur J Pharmacol 82:29–35.
Shannon M, Battaglia G, Glennon RA, Titeler M (1984) 5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol 102:23–29.
Sills MA, Wolfe BB, Frazer A (1984) Determination of selective and non-selective compounds for the 5-HT1A and 5-HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 231:480–487.
Spiegel R (1981) Increased slow-wave sleep in man after several serotonin antagonists. In: Sleep 1980. Karger, Basel, pp 275–278.
Titeler M, Herrick K, Lyon RA, McKenney JD, Glennon RA (1985) [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors. Eur J Pharmacol 117:145–146.
Tricklebank MD, Forler C, Fozard JR (1984) The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-proplylamino)tetralin in the rat. Eur J Pharmacol 106:271–282.
Trulson ME, Jacobs BL (1979) Raphe unit activity in freely moving cats: correlation with level of behavioral arousal. Brain Res 163:135–150.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dugovic, C., Wauquier, A., Leysen, J.E. et al. Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat. Psychopharmacology 97, 436–442 (1989). https://doi.org/10.1007/BF00439544
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00439544